Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Rein Therapeutics Inc. (RNTX) had Return on Tangible Equity of 12.60% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.50M |
|
-- |
|
-- |
|
$5.61M |
|
$-5.61M |
|
$0.11M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.61M |
|
$-5.61M |
|
21.92M |
|
21.92M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$8.33M |
|
$0.00M |
|
$49.30M |
|
$57.63M |
|
$5.98M |
|
-- |
|
$46.78M |
|
$52.75M |
|
$4.87M |
|
$-43.66M |
|
$4.87M |
|
22.00M |
|
| Cash Flow Statement Financials | |
$-6.17B |
|
-- |
|
$738.00M |
|
$12.87B |
|
$7.43B |
|
$-5.44B |
|
$264.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.17B |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-112.86% |
|
|
Return on Tangible Equity |
12.60% |
-9.55% |
|
-112.86% |
|
$0.22 |
|
$-281.76 |
|
$-281.76 |
|